Early Access to Medicines Scheme (EAMS) positive scientific opinion: Dupilumab in the treatment of children aged 6 to 11 years of age with severe atopic dermatitis (allergic eczema)

For the purpose of EAMS, dupilumab is being made available to children 6 to 11 years of age with severe atopic dermatitis who are candidates for systemic therapy and where existing systemic therapies are not advisable.

Source:

Medicines and Healthcare products Regulatory Agency